- Home
- TPST vs ECOR Comparison
TPST vs ECOR Comparison
Compare TPST & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- ECOR
- Stock Information
- Founded
- TPST 2011
- ECOR 2005
- Country
- TPST United States
- ECOR United States
- Employees
- TPST N/A
- ECOR N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- TPST Health Care
- ECOR Health Care
- Exchange
- TPST Nasdaq
- ECOR Nasdaq
- Market Cap
- TPST 45.5M
- ECOR 37.1M
- IPO Year
- TPST N/A
- ECOR 2018
- Fundamental
- Price
- TPST $11.02
- ECOR N/A
- Analyst Decision
- TPST Hold
- ECOR Strong Buy
- Analyst Count
- TPST 3
- ECOR 2
- Target Price
- TPST $30.00
- ECOR $25.50
- AVG Volume (30 Days)
- TPST 45.5K
- ECOR 45.7K
- Earning Date
- TPST 11-11-2025
- ECOR 11-12-2025
- Dividend Yield
- TPST N/A
- ECOR N/A
- EPS Growth
- TPST N/A
- ECOR N/A
- EPS
- TPST N/A
- ECOR N/A
- Revenue
- TPST N/A
- ECOR $27,700,000.00
- Revenue This Year
- TPST N/A
- ECOR $24.48
- Revenue Next Year
- TPST N/A
- ECOR $44.35
- P/E Ratio
- TPST N/A
- ECOR N/A
- Revenue Growth
- TPST N/A
- ECOR 30.16
- 52 Week Low
- TPST $5.35
- ECOR $4.16
- 52 Week High
- TPST $20.67
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- TPST 58.22
- ECOR 46.23
- Support Level
- TPST $8.87
- ECOR $4.86
- Resistance Level
- TPST $11.07
- ECOR $5.28
- Average True Range (ATR)
- TPST 0.47
- ECOR 0.25
- MACD
- TPST 0.07
- ECOR 0.03
- Stochastic Oscillator
- TPST 87.66
- ECOR 43.40
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.